ResMed (RMD) PT Raised to $260 at Piper Sandler; 'FQ2 Print Solid Across-The-Board'
Tweet Send to a Friend
Piper Sandler analyst Adam Maeder raised the price target on ResMed (NYSE: RMD) to $260.00 (from $252.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
